In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
about
Current and emerging azole antifungal agentsIn vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida sppIn vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolatesIn vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infectionUse of voriconazole in treatment of Scedosporium apiospermum infection: case report.In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implicationsStable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998.Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution methodIn vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and AfricaEfficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.In vitro evaluation of voriconazole against some clinically important fungiVariability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.Comparison of Etest with modified broth microdilution method for testing susceptibility of Aspergillus spp. to voriconazoleComparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.
P2860
Q24550733-25EA2DDF-7296-4423-9F96-43E58CEF1452Q28369323-56A59828-8C7C-442A-9686-323373862F87Q28379300-76DA41AC-28B6-4AC0-8E5A-4FEAA55A3F93Q28379320-DEF9F610-5026-45CA-A408-2E98E14428BEQ28379437-A37B3876-4EBC-47FA-96CC-A67BC635488BQ28379496-DEC06794-7006-47C1-BF8B-86F5D750E5C3Q33667583-E11FA1C5-6DB1-4655-AB09-35004745D3ABQ33676770-8DCAB5A1-F65A-4947-B769-9316B5F5E68BQ33683250-C9AC8025-5098-46D0-9677-D1557CC229EDQ33962343-524F0DAB-9EAD-448B-9476-47DFAD7CAD6DQ33965636-33E2C9F9-0367-4469-9C59-9615CAB1DA8DQ33971045-F6F67649-0506-484E-BE1D-2E6C18640577Q33975945-60FB7F78-AC05-4B5F-9AB2-DEA568354EC5Q33980836-ED4EFB23-6D51-445E-A92B-9F1F14E4C547Q34109559-C8C4ABDE-2BD0-4ADF-B9E4-D0FF29684696Q34431984-38C431FA-C1F4-499E-B346-9FEE35D73CE2Q34749162-B6F43F81-CE5D-4C6F-B758-174AA44A7E16Q35134300-56E8BDFC-371C-4110-BD0F-094212421E13Q35137870-2B47A234-AD5D-4885-A0BA-49F76DA56BDEQ35635830-F1578A65-D55F-458D-965E-9220A86C769BQ37058054-5384BC98-8D35-4647-ACE2-9C1B0DB2BB2EQ39473715-81C352A8-2C72-4179-B50A-3C3044C67670Q39557483-4DF51FFE-7226-4FC6-950D-D90A8A941030Q39652421-70253625-DAEE-4643-94C3-1355339F992DQ39652561-AC66294E-1396-4041-BE7B-EA675A968E4EQ39652863-371DB9C3-34A2-4158-8DC5-E3787AD6B98C
P2860
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro studies of two triazo ...... azole) against Candida species
@ast
In vitro studies of two triazo ...... azole) against Candida species
@en
In vitro studies of two triazo ...... azole) against Candida species
@nl
type
label
In vitro studies of two triazo ...... azole) against Candida species
@ast
In vitro studies of two triazo ...... azole) against Candida species
@en
In vitro studies of two triazo ...... azole) against Candida species
@nl
prefLabel
In vitro studies of two triazo ...... azole) against Candida species
@ast
In vitro studies of two triazo ...... azole) against Candida species
@en
In vitro studies of two triazo ...... azole) against Candida species
@nl
P356
P1476
In vitro studies of two triazo ...... azole) against Candida species
@en
P2093
P304
P356
10.1128/AAC.40.8.1948
P407
P577
1996-08-01T00:00:00Z